Tet-Regulated RNAi for Chemotherapy-Resistant Leukemia Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies are ineffective against chemotherapy-resistant leukemias, particularly those involving MLL gene rearrangements, as they fail to target specific genetic vulnerabilities in cancer cells.
Innovation Solution
The use of tet-regulated RNAi technology to selectively knockdown essential genes in leukemia cells, such as RPA3, RRM1, and MYB, using siRNAs or shRNAs, which are delivered via viral vectors and induced by doxycycline, to inhibit cancer cell proliferation and induce apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat leukemia, then it can address some cancer cells, but it fails to effectively treat chemotherapy-resistant leukemias and causes harm to normal cells
Solution Approach 1:
The invention segments the therapeutic approach by using RNA interference to specifically silence individual genes (such as MLL, HoxA9, Meis1, and other target genes identified in the patent) that are critical for leukemia cell survival. This gene-by-gene silencing strategy allows selective targeting of cancer cells with specific genetic vulnerabilities while leaving normal cells unaffected, thereby resolving the contradiction between therapeutic efficacy and harm to normal cells
Solution Approach 2:
The patent applies local quality by tailoring the RNAi therapy to the specific genetic profile of each leukemia patient. By identifying and targeting the particular genes that are overexpressed or mutated in the patient's cancer cells (such as MLL fusion genes, HoxA9, Meis1, or other leukemia-specific targets), the treatment achieves high specificity for cancer cells while preserving normal cellular function, thus improving therapeutic efficacy without damaging normal cells
2Measurement precision
If RNAi technology is used to specifically target cancer genes, then therapeutic precision is improved, but the complexity of identifying and validating target genes increases
Solution Approach 1:
The patent employs preliminary action by using genomic analysis and gene expression profiling to identify candidate target genes (such as MLL, HoxA9, Meis1, and other leukemia-associated genes) before initiating RNAi therapy. This pre-identification and validation process, which may involve in vitro screening and in vivo modeling, simplifies the subsequent clinical implementation by establishing a clear roadmap of target genes that require specific RNAi molecules, thereby reducing the complexity of target identification while maintaining high targeting precision
Solution Approach 2:
The invention incorporates feedback mechanisms through monitoring of gene expression levels and tumor response to RNAi therapy. By measuring the expression levels of target genes (such as MLL, HoxA9, Meis1) and assessing tumor burden through biomarkers or imaging, the treatment can be adjusted to optimize efficacy. This feedback loop simplifies the overall process by providing real-time information on which genes are effectively silenced and whether alternative targets should be pursued, thereby managing the complexity of gene identification and validation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves potent and durable remissions in chemotherapy-resistant leukemia models by specifically targeting and depleting cancer cells, while sparing normal cells, thereby providing a rational basis for designing targeted cancer therapies.
Implementation Method 1
RNA interference (RNAi) technology enables specific suppression of the expression of virtually any gene and provides a new tool for drug target discovery, validation, and therapy
Data Source
AI summary
Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.